CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022

Ruihao Huang; Qin Wen; Xi Zhang

doi:10.1186/s13045-023-01435-3

CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022

J Hematol Oncol. 2023 Apr 7;16(1):35. doi: 10.1186/s13045-023-01435-3.

Authors

Ruihao Huang¹, Qin Wen¹, Xi Zhang^{2

3}

Affiliations

¹ Medical Center of Hematology, Xinqiao Hospital. State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University, Chongqing, China.
² Medical Center of Hematology, Xinqiao Hospital. State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University, Chongqing, China. zhangxxi@sina.com.
³ Jinfeng Laboratory, Chongqing, China. zhangxxi@sina.com.

Abstract

Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a limited proliferative capacity. Recently, progress in CAR-NK cell therapy has been made in NK cell engineering, target design and combination with other agents to treat relapsed or refractory hematological malignancies, especially acute myeloid leukemia and multiple myeloma. This correspondence summarizes the preclinical and clinical updates for universal CAR-NK cell therapy reported at the ASH 2022 annual meeting.

Keywords: AML; CAR NK cell therapy; MM; mAb.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cell- and Tissue-Based Therapy
Hematologic Neoplasms* / therapy
Humans
Immunotherapy, Adoptive / adverse effects
Killer Cells, Natural
Multiple Myeloma* / therapy